<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20221024056284N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-10-24</date_registration>
      <primary_sponsor>Rasht University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of demineralized dentin graft and freeze-dried bone allograft for alveolar ridge preservation after tooth extraction</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation of dimensional changes in bone and soft tissue thickness using demineralized dentin graft and freeze-dried bone allograft for alveolar ridge preservation in maxillary -pre molar tooth sockets. Randomized clinical trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-10-25</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>16</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/94192</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Random Sequence Generation: Treatment allocation will be performed in a 1:1 ratio using permuted block randomization with variable block sizes of 4 and 6 to minimize the predictability of the allocation sequence and reduce selection bias.

Software and Independence of Sequence Generation: The randomization sequence will be generated by a biostatistician who is completely independent of treatment delivery, participant recruitment, surgery, and outcome assessment, using validated statistical software (R version 4.5 with the blockrand package or the online Sealed Envelope randomization service), Blinding description: Due to the inherent physical differences between the preparation of autogenous dentin particles and the use of commercially packaged bone graft powder, blinding of the surgeon and participants is not feasible. Therefore, blinding will be implemented according to the roles of the individuals involved, in accordance with the CONSORT guidelines for non-pharmacological treatments.

**Surgeon:** The operating surgeon will necessarily be aware of the type of graft material used and will therefore be unblinded.

**Participant:** Participants will be aware of the treatment procedures and the collection of their extracted teeth; therefore, they will not be blinded.

**Outcome Assessor Blinding:** Measurements of bone width and soft tissue thickness on cross-sectional CBCT images obtained at baseline and four months after the intervention will be performed by an independent oral and maxillofacial radiologist. All image files will be de-identified and provided to the radiologist without patient names, imaging time points, or treatment group information to ensure blinding.

**Data Analyst Blinding:** The statistical analyst will receive the data using neutral group codes (e.g., Group A and Group B) and will remain unaware of the group identities until the statistical modeling and extraction of the final results have been completed.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Alveolar Ridge Preservation Following Maxillary Premolar Extraction.</hc_freetext>
      <i_freetext>Intervention 1: Intervention Group 1 (DDG Group): After obtaining the baseline CBCT scan for patients in the DDG group, patients will rinse their mouths with 0.12% chlorhexidine mouthwash for one minute. Local anesthesia will then be administered simultaneously to the designated premolar and third molar using 2% lidocaine with 1:80,000 epinephrine. Soft tissue thickness will subsequently be assessed using an endodontic file and a gauge. The third molar and premolar will be extracted with minimal trauma using a flapless technique with a periotome and surgical forceps (Nordent Manufacturing Inc., IL, USA). Following tooth extraction, granulation tissue will be thoroughly curetted from the extraction sockets, which will then be irrigated with normal saline. The integrity of the bony walls of the premolar socket will be assessed using a Williams probe (Nordent Manufacturing Inc.), and the transverse bone dimensions will be recorded using a gauge. In the DDG group, the extracted third molar will be used to prepare the graft material. For this purpose, the remaining periodontal ligament (PDL), cementum, soft tissue, and any carious lesions will be removed using a high-speed finishing bur under continuous irrigation with sterile saline. The pulp tissue will be removed using sterile endodontic files, and the tooth will be ground into fine particles using a hand-operated bone mill (Bone Mill, JUYA, Pakistan). The particles will then be immersed in 0.6 N hydrochloric acid for 30 minutes for demineralization. Subsequently, they will be rinsed twice with normal saline and dried using sterile gauze. Finally, the premolar socket will be densely filled with the prepared DDG particles. An absorbable collagen membrane (cenomembrane, Tissue Regeneration Corp., Kish Island, Iran), with a medium thickness of 0.6–0.9 mm, will be placed to cover the socket and graft material. The membrane will be secured using the open membrane approach and an internal crisscross knot with 4-0 monofilament nylon sutures (Supalon, Supa, Iran). After four months, a second CBCT scan will be obtained to assess dimensional changes in the alveolar ridge. At the second appointment, four months after grafting, second-stage surgery will be performed for implant placement. Patients will first rinse their mouths with 0.12% chlorhexidine mouthwash. Following local anesthesia with 2% lidocaine and 1:80,000 epinephrine at the designated site, soft tissue thickness will be measured. A full-thickness mucoperiosteal flap will then be elevated, and the clinical bone width will be measured again using a surgical gauge. Finally, in both groups, regular-diameter dental implants from the DIO implant system will be placed at the grafted sites according to the standard surgical protocol. Intervention 2: Intervention Group 2 (FDBA Group): After obtaining the baseline CBCT scan, patients in the FDBA group will rinse their mouths with 0.12% chlorhexidine mouthwash for one minute. Local anesthesia will then be administered to the designated premolar using 2% lidocaine with 1:80,000 epinephrine. Soft tissue thickness will subsequently be assessed using an endodontic file and a gauge. The designated premolar will then be extracted with minimal trauma using a flapless technique with a periotome and surgical forceps (Nordent Manufacturing Inc., IL, USA). Following tooth extraction, granulation tissue will be thoroughly curetted from the extraction socket, which will then be irrigated with normal saline. The extracted third molar will not be used as graft material in this group. The integrity of the socket walls will subsequently be assessed using a Williams probe (Nordent Manufacturing Inc.), and the transverse bone dimensions will be measured using a gauge. The extraction socket will be densely filled and reconstructed using FDBA (150–1000 μm, CenoBone®, Tissue Regeneration Corp., Kish Island, Iran). After the socket has been filled, the entrance to the grafted socket will be covered with an absorbable collagen membrane (Cenomembrane, Tissue Regeneration Corp., Kish Island, Iran), with a thickness of 0.6–0.9 mm, using the open membrane approach. The membrane will be secured with an internal crisscross suture using 4-0 monofilament nylon sutures (Supalon, Supa, Iran). Standard postoperative instructions, including antibiotic therapy, analgesics, and chlorhexidine mouthwash, will be provided to the patients. Sutures will be removed after 10–14 days. After four months, a second CBCT scan will be obtained to assess dimensional changes in the alveolar ridge. At the second appointment, four months after grafting, second-stage surgery will be performed for implant placement. Patients will first rinse their mouths with 0.12% chlorhexidine mouthwash. Following local anesthesia with 2% lidocaine and 1:80,000 epinephrine at the designated site, soft tissue thickness will be measured. A full-thickness mucoperiosteal flap will then be elevated, and the clinical bone width will be measured again using a surgical gauge. Finally, in both groups, regular-diameter dental implants from the DIO implant system will be placed at the grafted sites according to the standard surgical protocol.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is Individual participant data will not be shared publicly due to participant confidentiality and privacy considerations. No additional information is available.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Ashkan Salari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>School of Dentistry, Guilan University of Medical Sciences, Saravan–Fouman Road, Rasht</address>
        <city>Rasht</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4194173774</zip>
        <telephone>+98 13 3348 6406</telephone>
        <email>Drashkan_salary@yahoo.com</email>
        <affiliation>Rasht University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Ashkan Salari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>School of Dentistry, Guilan University of Medical Sciences, Saravan–Fouman Road, Rasht</address>
        <city>Rasht</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4194173774</zip>
        <telephone>+98 13 3348 6406</telephone>
        <email>Drashkan_salary@yahoo.com</email>
        <affiliation>Rasht University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age ≥ 18 years
Presence of a non-restorable maxillary premolar and a non-restorable maxillary third molar
Extraction sockets with less than 50% buccal bone loss</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Presence of acute or chronic infection or local pathology at the intended grafting site
Presence of parafunctional habits
Implant placement limitations, such as insufficient vertical bone height
Use of medications that may interfere with bone healing, such as corticosteroids, hormone therapy, or bisphosphonates
History of uncontrolled systemic diseases or conditions that may interfere with bone healing, including smoking, diabetes mellitus, immunosuppression, fibrous dysplasia, bleeding disorders, hyperparathyroidism, pregnancy, or a history of head and neck radiotherapy or chemotherapy within the previous five years</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>K08.2</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Atrophy of edentulous alveolar ridge</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Surgery</i_code>
      <i_code>Treatment - Surgery</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention Group 1 (DDG Group): After obtaining the baseline CBCT scan for patients in the DDG group, patients will rinse their mouths with 0.12% chlorhexidine mouthwash for one minute. Local anesthesia will then be administered simultaneously to the designated premolar and third molar using 2% lidocaine with 1:80,000 epinephrine. Soft tissue thickness will subsequently be assessed using an endodontic file and a gauge. The third molar and premolar will be extracted with minimal trauma using a flapless technique with a periotome and surgical forceps (Nordent Manufacturing Inc., IL, USA). Following tooth extraction, granulation tissue will be thoroughly curetted from the extraction sockets, which will then be irrigated with normal saline. The integrity of the bony walls of the premolar socket will be assessed using a Williams probe (Nordent Manufacturing Inc.), and the transverse bone dimensions will be recorded using a gauge. In the DDG group, the extracted third molar will be used to prepare the graft material. For this purpose, the remaining periodontal ligament (PDL), cementum, soft tissue, and any carious lesions will be removed using a high-speed finishing bur under continuous irrigation with sterile saline. The pulp tissue will be removed using sterile endodontic files, and the tooth will be ground into fine particles using a hand-operated bone mill (Bone Mill, JUYA, Pakistan). The particles will then be immersed in 0.6 N hydrochloric acid for 30 minutes for demineralization. Subsequently, they will be rinsed twice with normal saline and dried using sterile gauze. Finally, the premolar socket will be densely filled with the prepared DDG particles. An absorbable collagen membrane (cenomembrane, Tissue Regeneration Corp., Kish Island, Iran), with a medium thickness of 0.6–0.9 mm, will be placed to cover the socket and graft material. The membrane will be secured using the open membrane approach and an internal crisscross knot with 4-0 monofilament nylon sutures (Supalon, Supa, Iran). After four months, a second CBCT scan will be obtained to assess dimensional changes in the alveolar ridge. At the second appointment, four months after grafting, second-stage surgery will be performed for implant placement. Patients will first rinse their mouths with 0.12% chlorhexidine mouthwash. Following local anesthesia with 2% lidocaine and 1:80,000 epinephrine at the designated site, soft tissue thickness will be measured. A full-thickness mucoperiosteal flap will then be elevated, and the clinical bone width will be measured again using a surgical gauge. Finally, in both groups, regular-diameter dental implants from the DIO implant system will be placed at the grafted sites according to the standard surgical protocol.</i_keyword>
      <i_keyword>Intervention Group 2 (FDBA Group): After obtaining the baseline CBCT scan, patients in the FDBA group will rinse their mouths with 0.12% chlorhexidine mouthwash for one minute. Local anesthesia will then be administered to the designated premolar using 2% lidocaine with 1:80,000 epinephrine. Soft tissue thickness will subsequently be assessed using an endodontic file and a gauge. The designated premolar will then be extracted with minimal trauma using a flapless technique with a periotome and surgical forceps (Nordent Manufacturing Inc., IL, USA). Following tooth extraction, granulation tissue will be thoroughly curetted from the extraction socket, which will then be irrigated with normal saline. The extracted third molar will not be used as graft material in this group. The integrity of the socket walls will subsequently be assessed using a Williams probe (Nordent Manufacturing Inc.), and the transverse bone dimensions will be measured using a gauge. The extraction socket will be densely filled and reconstructed using FDBA (150–1000 μm, CenoBone®, Tissue Regeneration Corp., Kish Island, Iran). After the socket has been filled, the entrance to the grafted socket will be covered with an absorbable collagen membrane (Cenomembrane, Tissue Regeneration Corp., Kish Island, Iran), with a thickness of 0.6–0.9 mm, using the open membrane approach. The membrane will be secured with an internal crisscross suture using 4-0 monofilament nylon sutures (Supalon, Supa, Iran). Standard postoperative instructions, including antibiotic therapy, analgesics, and chlorhexidine mouthwash, will be provided to the patients. Sutures will be removed after 10–14 days. After four months, a second CBCT scan will be obtained to assess dimensional changes in the alveolar ridge. At the second appointment, four months after grafting, second-stage surgery will be performed for implant placement. Patients will first rinse their mouths with 0.12% chlorhexidine mouthwash. Following local anesthesia with 2% lidocaine and 1:80,000 epinephrine at the designated site, soft tissue thickness will be measured. A full-thickness mucoperiosteal flap will then be elevated, and the clinical bone width will be measured again using a surgical gauge. Finally, in both groups, regular-diameter dental implants from the DIO implant system will be placed at the grafted sites according to the standard surgical protocol.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Change in Alveolar Ridge Width. Timepoint: At baseline, before tooth extraction and alveolar ridge preservation, and four months after the intervention, before implant placement surgery. Method of measurement: Alveolar ridge width will be measured on standardized cross-sectional cone-beam computed tomography images obtained at baseline and four months after the intervention. Measurements will be performed by an independent oral and maxillofacial radiologist blinded to group allocation. The change in ridge width will be calculated as the four-month measurement minus the baseline measurement.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Change in soft tissue thickness. Timepoint: At baseline, before tooth extraction and alveolar ridge preservation, and four months after alveolar ridge preservation, before the start of implant placement surgery. Method of measurement: Soft tissue thickness at the alveolar ridge will be measured before tooth extraction and four months after alveolar ridge preservation, initially using an endodontic file and subsequently using a surgical gauge. Measurements will be recorded in millimeters.</sec_outcome>
      <sec_outcome>Need for additional bone grafting at the time of implant placement. Timepoint: Four months after alveolar ridge preservation, during implant placement surgery. Method of measurement: The need for additional bone grafting following implant placement will be determined by the surgeon's clinical assessment of the bone thickness surrounding the implant and recorded as yes or no.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Rasht University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2026-10-22</approval_date>
        <contact_name>Ethics committee of Guilan University of Medical Sciences</contact_name>
        <contact_address>Namjoo Street, Shahid Siadati Street, Opposite 17 Shahrivar Hospital, Rasht Rasht Guilan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
